SHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sotera Health Co (SHC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong fundamentals, positive analyst sentiment, and improving financial performance outweigh the current technical weakness and insider selling. The stock's potential for sustainable growth in the medical device sterilization market makes it a solid choice for long-term investment.
The technical indicators show a mixed picture. The MACD histogram is negative and expanding, indicating bearish momentum. The RSI is at 31.223, which is neutral but approaching oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its support level of 16.222, suggesting limited downside risk in the short term.
Analysts have raised price targets recently, with Citi and Piper Sandler projecting a target of $23-$24, citing strong fundamentals and improved market demand.
The company reported a 5.7% revenue increase in 2025 and projects further growth in
Hedge funds are significantly increasing their positions, with a 140.83% rise in buying activity over the last quarter.
Insiders are selling, with a 131.94% increase in selling activity over the last month.
Q4 revenue fell short of expectations by $41.63 million, despite EPS exceeding forecasts.
Technical indicators suggest bearish momentum in the short term.
Sotera Health reported strong financial performance in Q4 2025. Revenue increased by 4.56% YoY to $303.44 million, net income surged by 182.91% YoY to $34.85 million, and EPS grew by 200% YoY to $0.12. Gross margin also improved to 53.68%, up 4.56% YoY. The company plans to invest $175-$225 million in capital expenditures to enhance production capacity, indicating confidence in future growth.
Analysts are overwhelmingly positive on SHC. Citi, RBC Capital, and Piper Sandler have all issued Buy or Overweight ratings with price targets ranging from $23 to $24. They highlight the company's strong fundamentals, high-margin profile, and sustainable growth potential in the medical device sterilization market.
